Search

Your search keyword '"Soler MJ"' showing total 378 results

Search Constraints

Start Over You searched for: Author "Soler MJ" Remove constraint Author: "Soler MJ"
378 results on '"Soler MJ"'

Search Results

1. Caracterización de la población con fracaso renal agudo durante la hospitalización por COVID-19 en España: tratamiento renal sustitutivo y mortalidad. Datos del Registro FRA-COVID SEN

2. Brain dysfunction in tubular and tubulointerstitial kidney diseases

4. Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study

5. Cell Sex and Sex Hormones Modulate Kidney Glucose and Glutamine Metabolism in Health and Diabetes

6. Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure

7. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA

8. Hospital pharmacist's roles and responsibilities with CAR-T medicines

9. Mild cognitive impairment and kidney disease: clinical aspects

10. Association of Candidate Gene Polymorphisms With Chronic Kidney Disease: Results of a Case-Control Analysis in the Nefrona Cohort

13. Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease

14. MP008SILAC-BASED PROTEOMICS OF PRIMARY HUMAN RENAL CELLS REVEALS A NOVEL LINK BETWEEN MALE SEX HORMONES AND IMPAIRED ENERGY METABOLISM IN DIABETIC KIDNEY DISEASE

17. EFFECT OF PRIME TYPE ON LEXICAL DECISION TIME

18. Impacto de la pandemia COVID-19 en los servicios de Nefrología españoles

19. Cardiorenal benefits of finerenone: protecting kidney and heart

20. What should European nephrology do with the new CKD-EPI equation?

21. Urinary angiotensin-converting enzyme 2 and metabolomics in COVID-19-mediated kidney injury

22. Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study

23. Role of light chain clearance in the recovery of renal function in multiple myeloma: another point of view

24. Practical approaches to building up a cardiorenal clinic

25. Intravenous fluid therapy in accordance with kidney injury risk: when to prescribe what volume of which solution

26. New aspects in cardiorenal syndrome and HFpEF

27. Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression—real-world clinical practice

28. Epidemiology of Immune-Mediated Glomerulopathies before and after SARS-CoV-2 Vaccination: A Tertiary Referral Hospital Experience

29. Novel strategies in nephrology: what to expect from the future?

30. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus

31. Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice

32. Association of renin–angiotensin system blockers with COVID-19 diagnosis and prognosis in patients with hypertension: a population-based study

33. Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI

34. Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?

35. Optimizing the timing of nephrology referral for patients with diabetic kidney disease

36. Acute tubulointerstitial nephritis induced by checkpoint inhibitors versus classical acute tubulointerstitial nephritis: are they the same disease?

37. Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practice

38. Safety of Obtaining an Extra Biobank Kidney Biopsy Core

39. Urinary Protein Profiling for Potential Biomarkers of Chronic Kidney Disease : A Pilot Study

40. Endothelin Receptor Antagonists in Kidney Disease

41. The Mitochondrion: A Promising Target for Kidney Disease

42. Redefining the Role of ADAM17 in Renal Proximal Tubular Cells and Its Implications in an Obese Mouse Model of Pre-Diabetes

43. Endothelial ADAM17 Expression in the Progression of Kidney Injury in an Obese Mouse Model of Pre-Diabetes

44. Acute kidney injury in patients treated with immune checkpoint inhibitors

45. COVID-19 infection and renal injury: where is the place for acute interstitial nephritis disease?

46. The Presence of ANCA in IgA Crescentic Nephropathy Does Not Lead to Worse Prognosis with Intensive Rescue Treatment

47. Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice

48. Long-Term Dynamic Humoral Response to SARS-CoV-2 mRNA Vaccines in Patients on Peritoneal Dialysis

49. Expert Clinical Management of Severe Immune-Related Adverse Events: Results from a Multicenter Survey on Hot Topics for Management

50. The Impact of Age on Mortality in Chronic Haemodialysis Population with COVID-19

Catalog

Books, media, physical & digital resources